Cellectis S.A.
CMVLF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$251.93M
Close$
$-1.19
134.3% downside
Current Fair Value
134.3% downsideOvervalued by 134.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $251.93 Million |
|---|---|
| Enterprise Value | $391.85 Million |
| Earnings per Share | $-0.7 |
| Beta | 2.75 |
| Outstanding Shares | 100,527,276 |
Return
| Return on Equity | -159.71% |
|---|---|
| Return on Assets | -24.53% |
| Return on Invested Capital | -37.36% |
Valuation & Multiples
| P/E Ratio | -1.61 |
|---|---|
| PEG | 17.44 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 6.92 |
| Enterprise Value to EBIT | -7.92 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.45 |
| Debt to Equity | 4.27 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.23
Consensus analyst estimateRevenue Estimate
$10.77 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.21
Consensus analyst estimateRevenue Estimate
$15.02 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Cellectis
227 employees
CEO: Andre Choulika
Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to dis...